Introduction
Beta-adrenoceptor-blocking agents are extensively used in the management of hypertension and ischaemic heart disease. These agents may also be used in acromegalic patients where hypertension and ischaemic heart disease occur commonly (Martins et al., 1977) . There is, however, some evidence that propranolol, alone in normal subjects (Imura et al., 1971; Maclaren, Taylor and Raiti, 1975) , and combined with glucagon in acromegalic subjects (Coutant, Vandeweghe and Vermeulen, 1977) , may increase growth hormone (GH) concentrations. The object of this study was to determine if chronic treatment with oxprenolol or propranolol in hypertensive patients is associated with elevation of GH, and to determine the influence of propranolol alone on GH levels in acromegalic patients. 
in GH levels (in the 3 responders) and of plasma propranolol concentration.
Discussion
In addition to dopaminergic control, the adrenergic system is an important regulator of growth hormone secretion. Alpha blockade and a stimulation suppress GH secretion, while 5-blockade augments GH secretion in both normal and acromegalic subjects (Cryer and Daughaday, 1977) . Chronic elevation of GH may be cardiotoxic in acromegaly (Martins et al., 1977) although its possible effects on an ischaemic or hypertensive heart is unknown. Acute treatment with propranolol has been shown by Imura et al. (1971) , and Maclaren et al. (1975) , to increase GH levels, however GH did not increase in a study by Lee, Thompson and Blizzard (1974) . In this study in active hypertensive patients, chronic treatment with non-selective centrally acting Pblockers was associated with elevation of GH, while a normal GH response to glucose loading has recently been noted by Day et al. (1979) in recumbent fasting hypertensive patients receiving chronic propranolol or atenolol therapy. Propranolol may increase the GH response to many stimuli including moderate exercise (Maclaren et al., 1975) ; however, more detailed studies are necessary to determine whether GH remains elevated for a greater part of the day in patients receiving 5-blockers. It has been suggested by Sherman et al. (1978) that oral contraceptives may induce growth and hormonal secretion in otherwise silent pituitary microadenomata, which occur in 5-10 % of the population, and it is also possible that term treatment with 5-blockers may facilitate the development of pituitary adenomata and acromegaly.
The variability in the response of some acromegalic patients to hypoglycaemia, propranololglucagon, thyrotrophin-releasing hormone and Ldopa has over the last decade led to the suggestion (Cryer and Daughaday, 1969; Goldfine, 1978) 
